News & Media

Miraculins Announces Improved Detection of Aggressive Prostate Cancer With Combination of PSP94 and Free Over Total PSA Ratio

WINNIPEG, Manitoba – February 10th, 2009 – Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to announce results which demonstrate that PSP94 in urine can be used to improve the performance of free over total (F/T) PSA ratio in detecting aggressive prostate cancer. The improvement offered by PSP94 is believed to be a novel discovery.

“The free PSA test is marketed by a number of large diagnostic companies and this discovery of the improvement offered by PSP94 is a tremendous addition to our prostate cancer package. We believe that this discovery could help significantly improve and differentiate the standard free PSA test,” said Christopher Moreau, President and Chief Executive Officer of Miraculins Inc.

In Miraculins’ recent immunoassay testing, the Company successfully demonstrated that standardized PSP94 combined with F/T PSA ratio was able to differentiate men with aggressive prostate cancer (Gleason Score of 7-10, n=18) from men with favorable pathologies (Gleason Score of 6 or less, BPH or healthy men, n=70) with a sensitivity of 94% and specificity of 49% (AUC=0.80). This result was much stronger than the individual performance of F/T PSA in the same samples, which had a sensitivity of 94% and specificity of 16%. When men with the confounding condition of hypertension were removed from testing, the combination yielded even better results and successfully separated the same populations with a sensitivity of 100% and a specificity of 84% (AUC=0.87, n=7 aggressive cancer and n=37 favorable pathologies).

“These results are important because they support the use of PSP94 in combination with F/T PSA ratio as a tool to help patients avoid unnecessary suffering from prostate cancer,” stated Dr. Stephen Frost, Director of Research and Development for Miraculins. “As prostate cancer is often slow-growing, a number of men are currently engaged in watchful waiting programs as opposed to more aggressive treatment regimens. With a reliable tool for determining prostate cancer aggressiveness, only the highest risk patients would require repeat biopsy and therefore the physical and psychological cost of biopsies for men with non-aggressive forms of the disease could be avoided. A tool of this type may also enable more men to pursue watchful waiting as a treatment option.”

“Additionally, a number of patients who have aggressive prostate cancer may not normally be referred to biopsy, such as men in the lower PSA range or those considered too old for PSA screening. These men could also benefit from a test which would allow those with aggressive forms of the disease to seek appropriate medical treatment,” added Dr. Frost.

“The need for improved, non-invasive diagnostic tools for determining the aggressiveness of prostate cancer is well known and interest in this research area is growing within the scientific and medical fields. We believe that our discovery can make a contribution to this effort,” concluded Moreau.

About Miraculins Inc.

Miraculins is a medical diagnostic development company focused on non-invasive tests for unmet clinical needs. Miraculins is bridging the gap between commercially available diagnostic tests and research conducted at leading research institutions around the world.

About F/T PSA Testing

PSA exists in several forms in the blood including bound to proteins and free (unbound). Free PSA is known to contribute to the diagnosis of prostate cancer when total PSA is modestly elevated, in addition to having been associated with prostate cancer aggressiveness in the literature. F/T PSA is based on a measurement of conventional (total) PSA and free PSA.

For more information, please contact:

Christopher J. Moreau
President and CEO
Miraculins Inc.
Ph: 204-477-7599
Fax: 204-453-1546

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, “forward-looking statements”). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Miraculins’ early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers’ willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Miraculins’ filings with Canadian securities regulatory authorities, as well as Miraculins’ ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release. Miraculins cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Miraculins’ forward-looking statements to make decisions with respect to Miraculins investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Miraculins cannot provide assurance that actual results will be consistent with these forward-looking statements. Miraculins undertakes no obligation to update or revise any forward-looking statement.